From June 24th to 26th, 2025, the Shanghai New International Expo Center welcomed the annual grand event of the global pharmaceutical industry - the 23rd World Pharmaceutical Raw Materials China Exhibition (CPHI China 2025) and the 18th World Pharmaceutical Machinery, Packaging Equipment and Materials China Exhibition (PMEC China 2025). As a highly influential exhibition in the industry, this year's CPHI & PMEC China attracted over 3,500 enterprises from more than 140 countries and regions around the world to participate. The exhibition area exceeded 230,000 square meters, setting a new record once again and fully demonstrating its status as an important platform for exchanges and cooperation in the global pharmaceutical industry. ​  Anhui Newman Fine Chemical Co., LTD., as a globally leading manufacturer of carbomer and acylates copolymers, made a grand appearance at this exhibition. With   good quality, innovative technological research and development, and professional service team, it shone brightly at the exhibition and attracted the attention of many domestic and foreign professional visitors. ​

During the exhibition, the booth of Anhui Newman was always bustling with people. We warmly welcome every visiting customer, patiently answer their questions, and introduce in detail the company's core products - the Carbomer series and their wide applications in the fields of medicine, cosmetics, personal care, etc. Newman Carbomer has won high recognition and praise from on-site customers with its unique performance advantages, such as efficient thickening, excellent suspending as excipient and rheology modifier. Not only that, but we  also  showcased a series of its latest developed products and application solutions, including the "Toxicology Preferred" Carbomer product tailored to different market demands and regulatory requirements, as well as innovative application cases in new drug formulations and high-end cosmetic formulas, fully demonstrating Anhui Newman's strong strength  in technological innovation.

During 2025 CPHI China, Anhui Newman highlighted the pharmaceutical-grade Carbomer closely related to human health, featuring the following varieties:

1） Carbomer homopolymer: carbomer homopolymer type A such as NM-Carbomer 971P, 71G, 981G.    And Carbomer Homopolymer Type B such as NM-Carbomer 974P, 934P, and Carbomer Homopolymer type C such as NM-Carbomer 970G.

2） Carbomer Copolymer: carbomer copolymer type A such as NM-Carbomer TR-2 P, and Carbomer copolymer type B such as NM-Carbomer TR-1P, and 1382G, and carbomer Copolymer Type C.

3） Carbomer interpolymer: Carbomer interpolymer Type A, such as NM-Carbomer 10G, Carbomer interpolymer type B such as carbomer 2020G.

All these polymers as excipients meet the requirements of major pharmacopoeia such as Chinese Pharmacopoeia 2020, US Pharmacopoeia USP/NF, European Pharmacopoeia EP, British Pharmacopoeia BP and other relevant regulations.

Newman Carbomer pharmaceutical excipients, such as rheological modifiers and tablet adhesives are widely used in pharmaceutical products. Moreover, it is also used as a suspension stabilizer, slow-release polymer, mucosal adhesive additive and biological enhancer. Our professional, technical and business teams, with rich experience and knowledge in drug product formulas, can provide customers with superior services. "Traditional" carbomer is synthesized using benzene, but the restrictions on the use of benzene in the application of pharmaceutical excipients are becoming increasingly strict. Our "Toxicology Preferred" carbomer can be synthesized both in ethyl acetate and in a mixed co-solvent of ethyl acetate and cyclohexane. It is recommended for use in all current new drug development projects. Thereby enhances the product's performance in use and meeting the highest safety standards. ​​

During meeting with customers, Anhui Newman gained a thorough understanding of the latest market demands and industry trends and collected valuable feedback. Many customers have given full recognition to the performance of Newman carbomer products in practical applications and expressed their willingness to further deepen cooperation. Meanwhile, Anhui Newman also took this opportunity to conduct extensive and in-depth technical exchanges and cooperation negotiations with upstream and downstream enterprises, research institutions, experts and scholars in the industry, jointly exploring new opportunities and challenges in the industry's development and contributing to promoting the collaborative innovation and development of the entire pharmaceutical industry chain. ​

Looking ahead, Anhui Newman will take this CPHI exhibition as a new starting point, continue to uphold the business philosophy of "technology leadership, innovation-driven, quality-oriented, and customer-first", actively participate in various domestic and international industry exhibitions and exchange activities, and constantly enhance the core competitiveness and brand influence of the enterprise. We look forward to once again showcasing our talents on more stages and working hand in hand with global partners to create an even brighter future.